Glomus Tumor: Disease Characteristics Research Report

Scope. This report concerns the soft-tissue glomus tumor, a perivascular/pericytic neoplasm showing differentiation toward modified smooth-muscle cells of the normal glomus body. It does not concern “glomus jugulare,” “glomus tympanicum,” or carotid-body tumors, which are paragangliomas with different cells of origin, genetics, management, and ontology mappings.

Evidence note. Glomus tumor is rare, and much of the literature consists of retrospective series and case reports. The strongest retrieved recent evidence comprised a 2023 NF1 surveillance guideline and the 2024 ClinicalTrials.gov update of a molecularly selected malignant-glomus-tumor trial. Some requested database fields could not be validated from accessible primary sources and are therefore marked as unconfirmed rather than inferred.

Table: This compact table summarizes core disease-knowledge-base facts for soft-tissue glomus tumor while clearly separating it from paraganglioma terminology. It emphasizes molecular drivers, NF1 association, malignant-disease trial evidence, and current evidence gaps relevant for structured curation.

1. Disease information

Definition and classification

A glomus tumor is usually a small, circumscribed neoplasm of uniform round glomus cells arranged around branching vessels. It belongs to the pericytic/perivascular tumor family. Most lesions are benign and occur in the distal extremities, especially the subungual region; extradigital, deep-soft-tissue, visceral, and very rarely malignant tumors occur.

ClinicalTrials.gov and MeSH index the entity as Glomus Tumor, MeSH D005918. The registry places it under vascular-tissue and connective/soft-tissue neoplasms. The trial terminology “Glomus Tumor, Malignant” confirms that this indexing includes the malignant soft-tissue entity rather than only paraganglioma. (NCT03422679 chunk 1, NCT03422679 chunk 2)

Identifiers and suggested mappings

• MeSH: D005918, Glomus Tumor—directly validated. (NCT03422679 chunk 2)
• MONDO: a separate current MONDO identifier could not be validated from the retrieved sources; curate against the live MONDO release rather than assigning an uncertain ID.
• OMIM/Orphanet: typical sporadic solitary glomus tumor does not have a single well-established Mendelian disease entry. Do not substitute entries for glomuvenous malformation caused by GLMN.
• ICD-10-CM: coding is site and behavior dependent, commonly under benign neoplasm of connective/other soft tissue or uncertain/unknown behavior when appropriate; there is no universally satisfactory disease-specific code.
• ICD-11: use morphology plus site/behavior coding after confirmation in the current release.
• Category: pericytic/perivascular soft-tissue neoplasm; usually benign, rarely malignant.
• Synonyms: glomus cell tumor, glomangioma, glomangiomyoma, solid glomus tumor. Strictly, the latter three may denote histologic variants and should not always be treated as exact synonyms. “Glomus jugulare tumor” is an excluded paraganglioma synonym.

This report synthesizes aggregated disease-level resources and published cohorts, not individual EHR-derived patient data. The ClinicalTrials.gov record is aggregated study-level information.

2. Etiology

Causal and genetic factors

Most solitary tumors are sporadic somatic neoplasms. The principal established molecular class has rearrangements joining the MIR143/MIR143HG locus to NOTCH1, NOTCH2, or NOTCH3. A vascular-NOTCH review reports that such fusions occur in “almost 50% of glomus tumours,” while a gene-fusion review notes their detection in both benign and malignant lesions. (gaudio2022notchsignallingin pages 10-11, mertens2016genefusionsin pages 19-20)

The strongest recognized constitutional association is neurofibromatosis type 1 (NF1), particularly with multiple or recurrent painful digital tumors. The 2023 ERN GENTURIS guideline states that in adulthood the risk of “glomus tumours of the digits” increases in NF1. This is an authoritative human guideline association, although it does not supply a penetrance estimate for glomus tumors. Published February 2023; DOI: 10.1016/j.eclinm.2022.101818. (carton2023erngenturistumour pages 7-8)

GLMN requires careful separation. Germline loss-of-function variants in GLMN cause autosomal-dominant glomuvenous malformations, historically called multiple glomangiomas. These vascular malformations overlap morphologically and terminologically with glomus tumors but are not equivalent to the typical solitary neoplasm. Variant-level ClinVar/gnomAD frequencies were not available in the retrieved evidence.

Somatic BRAF p.Val600Glu has been reported in a minority of glomus tumors and appears enriched among lesions with malignant histologic features, but an exact frequency was not recoverable from accessible full text and should not be entered without verification of the primary cohort.

Environmental, infectious, lifestyle, and protective factors

No reproducible causal association with smoking, alcohol, diet, toxins, radiation, occupation, infection, or trauma has been established. Trauma may bring a painful lesion to attention but is not a proven cause. No validated genetic or environmental protective factor is known. There is no demonstrated gene–environment interaction.

3. Phenotypes

The classic digital phenotype is a small, intensely painful nodule with pinpoint tenderness and cold hypersensitivity. Pain can be spontaneous or pressure-provoked and may substantially impair sleep, manual work, typing, footwear tolerance, and daily activities despite the tumor’s small size. Formal EQ-5D, SF-36, or PROMIS studies and reliable phenotype frequencies are lacking.

Suggested structured phenotypes include:

• Localized pain: symptom; often severe and chronic/episodic; HP:0012531 Pain.
• Tenderness: clinical sign, typically sharply localized; HP:0033748 Tenderness.
• Cold-provoked pain/hypersensitivity: symptom; no confidently validated dedicated HPO identifier was established from retrieved evidence, so use a curated cold-sensitivity child term if available.
• Subungual blue-red nodule or nail-bed discoloration: physical manifestation; suggest HP:0001597 Abnormality of the nail plus a more specific nail-bed term if available.
• Nail plate distortion: sign in larger or longstanding subungual lesions; HP:0001597.
• Gastric or visceral presentation: abdominal pain, gastrointestinal bleeding, anemia, or an incidental submucosal mass; site-specific evidence is predominantly small series and case reports.
• Malignant disease: enlarging deep mass, local invasion, recurrence, or metastasis; highly variable and exceptionally rare.

Typical onset is in adolescence through middle adulthood, but pediatric and older-adult cases occur. Solitary digital disease is often reported more frequently in women, whereas extradigital lesions show less consistent sex bias. The disease is usually indolent until excision; symptoms may persist for years because of diagnostic delay.

4. Genetic and molecular information

MIR143–NOTCH alterations

MIR143–NOTCH1/2/3 fusions are recurrent somatic structural variants and probably the most characteristic known drivers. The available review states that they occur in nearly half of tumors, and another review explicitly records them in both benign and malignant lesions. (gaudio2022notchsignallingin pages 10-11, mertens2016genefusionsin pages 19-20)

Proposed consequence: juxtaposition of the active smooth-muscle/perivascular MIR143 regulatory region with a truncated NOTCH receptor drives ligand-independent or otherwise dysregulated NOTCH transcriptional output. This promotes survival and proliferation of glomus/pericytic-lineage cells. The causal chain is therefore:

somatic rearrangement → constitutive NOTCH signaling → altered perivascular-cell differentiation/proliferation → vascular-rich glomus-cell nodule → focal tenderness and cold-provoked pain.

Suggested annotations: NOTCH1, NOTCH2, NOTCH3, MIR143HG; GO:0007219 Notch signaling pathway; GO:0048514 blood-vessel morphogenesis; CL:0000669 pericyte.

Other alterations and differential molecular diagnoses

BRAF V600E defines a smaller MAPK-pathway subset. Testing may be informative in malignant, metastatic, histologically atypical, or diagnostically difficult tumors, although it is not required for routine classic digital lesions.

GLI1-rearranged or GLI1-amplified pericytic tumors may mimic glomus tumor. In a 2019 comparator series of ten GLI1-amplified tumors, all ten had GLI1 amplification, nine had CDK4 co-amplification, and eight had MDM2 co-amplification; four had at least 15 mitoses per ten high-power fields and three had necrosis. The authors concluded that amplification may provide an alternative mechanism of GLI1 activation in an emerging malignant soft-tissue-tumor group. DOI: 10.1038/s41379-019-0293-x, received February 18 and accepted May 1, 2019. These are differential-diagnosis data, not frequencies in conventional glomus tumor. (agaram2019gli1amplificationsexpandthe pages 2-4, agaram2019gli1amplificationsexpandthe pages 1-2)

No validated modifier gene, recurrent epigenetic class, germline carrier frequency, or protective allele has been established for sporadic solitary tumors. WGS/WES studies remain too small for dependable population-frequency inference.

5. Environmental information

No toxin, radiation exposure, pollution source, occupational exposure, lifestyle behavior, or infectious agent is recognized as causal. Glomus tumor is noncommunicable and noninfectious. Consequently, CTD-style chemical–disease causal annotations should not be added without direct experimental evidence. CHEBI annotations are relevant only to administered diagnostic agents or treatments, not etiology.

6. Mechanism and pathophysiology

Normal glomus bodies are specialized arteriovenous thermoregulatory structures in acral skin. Modified smooth-muscle glomus cells surround vascular channels and regulate blood flow. Neoplastic proliferation produces a compact, vascular-rich nodule in a confined and highly innervated space. Pressure, vascular tone changes, and cold-triggered contraction plausibly explain the disproportionate pain.

Upstream: MIR143–NOTCH rearrangement, less often MAPK activation such as BRAF V600E, or NF1-associated RAS pathway dysregulation.

Intermediate: abnormal NOTCH/RAS-MAPK signaling, perivascular-cell proliferation, and altered smooth-muscle differentiation. NOTCH has broad physiological roles in vascular genesis, remodeling, arterial–venous identity, branching, and homeostasis; therefore, its dysregulation is biologically coherent in a pericytic tumor. DOI: 10.1098/rsob.220004, published April 2022. (gaudio2022notchsignallingin pages 10-11)

Downstream: circumscribed tumor growth around vessels, local compression and stimulation of sensory fibers, severe tenderness, and cold-sensitive pain. Malignant progression adds high mitotic activity, atypical mitoses, genomic instability, invasion, and metastatic capability.

Suggested terms include CL:0000669 pericyte; GO:0007219 Notch signaling; GO:0000165 MAPK cascade; GO:0001525 angiogenesis; GO:0048514 blood-vessel morphogenesis; GO:0008283 cell population proliferation; GO:0006939 smooth-muscle contraction. Relevant cellular compartments include plasma membrane, cytoplasm, and nucleus for receptor cleavage and transcriptional signaling. No reproducible metabolomic, lipidomic, proteomic, single-cell, spatial-transcriptomic, or CRISPR-screen signature is presently established.

7. Anatomical structures affected

The prototypic sites are the distal fingers and toes, especially the subungual nail bed and fingertip pulp. Other cutaneous and deep-soft-tissue locations include forearm, arm, leg, trunk, head/neck, and peripheral nerve. Visceral tumors occur most characteristically in the gastric wall and more rarely in respiratory, genitourinary, bone, and other sites.

At tissue level, the lesion involves connective/soft tissue surrounding small vascular channels and comprises glomus cells with pericytic/smooth-muscle differentiation. Suggested mappings include CL:0000669 pericyte; UBERON:0002389 finger; UBERON:0000945 stomach; and current-release UBERON terms for nail bed, toe, skin, subcutaneous tissue, and vascular wall. Digital tumors are usually unilateral and solitary; multiplicity should prompt consideration of NF1 or glomuvenous malformation.

8. Temporal development

Onset is usually insidious. Small lesions may produce chronic intermittent or progressively intrusive pain for years without substantial growth. There is no accepted stage system for benign disease. A practical course classification is localized benign, incompletely excised/recurrent, uncertain malignant potential, and malignant/metastatic.

Following complete excision, pain often resolves promptly. Early postoperative persistence or rapid recurrence suggests residual tumor; late recurrence can represent regrowth or a second lesion. Malignant tumors have a variable course and may metastasize after a prolonged interval, so long-term surveillance is reasonable. No validated critical prevention window or spontaneous-remission pattern is known.

9. Inheritance and population

Robust population-based incidence and prevalence per 100,000 are unavailable. Frequently repeated proportions in narrative reviews derive from surgical pathology archives rather than population registries and should not be interpreted as prevalence.

Most solitary tumors are sporadic and nonfamilial. NF1 is autosomal dominant, with variable expressivity, and confers increased susceptibility to digital glomus tumors. The 2023 guideline specifically places digital glomus tumors among neoplasms whose risk increases in adults with NF1. (carton2023erngenturistumour pages 7-8)

Familial multiple glomuvenous malformation due to GLMN is autosomal dominant with incomplete penetrance and variable expression, but it is a related vascular-malformation disorder rather than a simple inheritance model for all glomus tumors. No genetic anticipation, consistent founder effect, consanguinity effect, germline mosaicism rate, or carrier frequency is established for conventional solitary glomus tumor. No convincing ethnic or geographic concentration is recognized.

10. Diagnostics

Clinical and imaging diagnosis

For a painful digital lesion, examination should document pinpoint tenderness, cold sensitivity, nail discoloration/deformity, and whether pressure or transient arterial occlusion changes pain. These bedside maneuvers can localize disease but do not replace pathology.

High-resolution ultrasonography may show a small hypoechoic hypervascular nodule. MRI typically shows a sharply defined lesion with low/intermediate T1 signal, high T2 signal, and strong enhancement, but very small tumors can be missed. Plain radiographs are usually normal, although longstanding subungual lesions may erode the distal phalanx.

Pathology

Definitive diagnosis is histopathologic. Typical lesions contain uniform round cells with sharply defined borders surrounding branching vessels. Variants include solid glomus tumor, glomangioma with a larger vascular component, and glomangiomyoma with spindle-cell/smooth-muscle maturation.

The expected immunophenotype is strong smooth-muscle actin and often h-caldesmon, calponin, vimentin, collagen IV, and laminin; desmin is variable. Cytokeratin, S100/SOX10, CD34, and endothelial markers are generally absent in tumor cells, though vessels label with CD31/ERG. Molecular confirmation by RNA sequencing, fusion panel, or NOTCH break-apart testing is most useful for atypical, deep, malignant, or diagnostically ambiguous lesions.

Differential diagnosis

• Hemangioma/venous malformation: vascular spaces dominate; endothelial cells rather than perivascular glomus cells constitute the lesion.
• Blue nevus/melanoma: melanocytic markers S100, SOX10, and melan-A support melanocytic lineage.
• Schwannoma/neuroma: neural morphology and diffuse S100/SOX10.
• Leiomyoma/angioleiomyoma: intersecting fascicles of spindle smooth-muscle cells rather than rounded glomus cells.
• Myopericytoma/myofibroma: concentric vessel-associated myoid growth or biphasic morphology.
• GIST in stomach: KIT/DOG1 expression and KIT/PDGFRA molecular alterations.
• Neuroendocrine tumor: keratin and neuroendocrine-marker expression.
• Paraganglioma: neuroendocrine chief cells with sustentacular S100/SOX10; fundamentally different entity.
• GLI1-altered pericytic tumor: molecular GLI1 alteration, often S100 positivity and malignant morphology; the 2019 series shows why molecular analysis can prevent misclassification. (agaram2019gli1amplificationsexpandthe pages 2-4, agaram2019gli1amplificationsexpandthe pages 1-2)

Routine WES/WGS, CMA, karyotyping, mitochondrial testing, repeat-expansion analysis, liquid biopsy, and population screening are not indicated. For multiple digital tumors, syndromic features, or family history, evaluate NF1 clinically and consider appropriate germline testing; consider GLMN testing for multiple glomuvenous lesions.

11. Outcome and prognosis

Localized benign tumors have an excellent prognosis and ordinarily do not affect life expectancy. Complete excision is usually curative. Morbidity before diagnosis is dominated by pain, sleep interruption, impaired hand use, reduced occupational function, and repeated ineffective treatment. Recurrence is mainly associated with incomplete excision, multifocal disease, or an initially missed satellite lesion.

Malignant glomus tumor is rare but can recur and metastasize, particularly to lung, liver, bone, and soft tissue. Histologic concern rises with marked nuclear atypia, atypical mitoses, high mitotic activity, and deep/large tumors, but modern WHO practice emphasizes cytologic atypia and atypical mitotic figures more than size/depth alone. No reliable 5- or 10-year survival estimate can be given because reported cohorts are very small and heterogeneous. Molecular markers such as BRAF or NOTCH fusion have not yet been validated as independent prognostic biomarkers.

12. Treatment

Localized disease

Complete surgical excision with preservation of the nail matrix, neurovascular structures, or involved organ is standard. A transungual approach gives direct access to central subungual lesions; lateral or periungual approaches may reduce nail-matrix injury for appropriately located tumors. Gastric lesions are generally treated by wedge/partial gastrectomy or selected endoscopic full-thickness techniques after multidisciplinary review. Suggested NCIT terms: Surgical Excision, Local Tumor Excision, Partial Gastrectomy, and Endoscopic Resection.

Analgesics and avoidance of cold may provide temporary symptomatic relief but do not eradicate the tumor. Rehabilitation is rarely required except after extensive surgery or prolonged functional avoidance.

Malignant or unresectable disease

Management should occur in a sarcoma multidisciplinary center. Resectable disease is treated surgically, sometimes with radiotherapy for local-control indications. There is no glomus-tumor-specific standard chemotherapy regimen; anthracycline-based soft-tissue-sarcoma therapy, pazopanib, or other agents may be considered case by case, with limited evidence.

Molecularly selected targeted therapy is investigational. NCT03422679 evaluated oral CB-103, a pan-NOTCH pathway inhibitor, in a phase I/IIA open-label basket study. Eligibility explicitly included surgically unresectable, locally advanced, or metastatic malignant glomus tumor after systemic therapy, or another cancer with a confirmed NOTCH1–4 activating lesion. The study enrolled 79 participants overall, used 28-day cycles, and assessed dose-limiting toxicity and objective response. It was terminated for a business reason, not because the registry established inefficacy; results were posted January 16, 2024. ClinicalTrials.gov NCT03422679. (NCT03422679 chunk 1, NCT03422679 chunk 2)

The linked phase I publication is Hanna et al., Cancer Research Communications, September 14, 2023, PMID 37712875, DOI: 10.1158/2767-9764.CRC-23-0333. The available registry does not provide a glomus-tumor-specific response rate; basket-level outcomes must not be attributed to this rare subgroup. (NCT03422679 chunk 2)

There is no established pharmacogenomic dosing guideline, approved gene/cell/RNA therapy, or proven checkpoint inhibitor strategy.

13. Prevention

No primary prevention, vaccine, prophylactic medication, or environmental intervention is available. Population, newborn, and carrier screening are not recommended.

Secondary prevention consists of early recognition and complete removal of symptomatic lesions. Individuals with NF1 should be educated to report focal digital pain, cold sensitivity, or nail changes. The ERN GENTURIS guideline recommends broad adult NF1 clinical assessment at least every three years and identifies digital glomus tumor as an adult risk, although it does not recommend routine imaging specifically for asymptomatic digits. (carton2023erngenturistumour pages 7-8)

Tertiary prevention includes complete excision, pathology review of atypical lesions, re-excision when margins are clinically concerning, and surveillance for malignant or recurrent disease. Genetic counseling is appropriate for NF1 or suspected GLMN-associated familial disease.

14. Other species and natural disease

Sporadic glomus-cell tumors have been reported rarely in companion animals, including cats and dogs, but available evidence consists primarily of isolated pathology reports. No breed predisposition, incidence, zoonotic potential, transmission pathway, or validated cross-species susceptibility estimate is established. Human NOTCH, NF1, BRAF, and GLMN pathways are evolutionarily conserved, but conservation alone does not establish an equivalent animal syndrome.

Suggested taxa for future curation are Homo sapiens, NCBI Taxon 9606; Canis lupus familiaris, 9615; Felis catus, 9685; Mus musculus, 10090. Veterinary cases are noninfectious and have no zoonotic significance.

15. Model organisms

No widely adopted disease-specific genetically engineered mouse, rat, zebrafish, organoid, or patient-derived xenograft model was identified. Existing mechanistic interpretation relies mainly on human tumor sequencing and general vascular-NOTCH models. The vascular review establishes that NOTCH regulates vessel development, branching, identity, and homeostasis, but these experiments are pathway models rather than faithful glomus-tumor models. (gaudio2022notchsignallingin pages 10-11)

Priority models would include conditional expression of a MIR143–NOTCH fusion in mural-cell lineages such as PDGFRB-, CSPG4-, or ACTA2-expressing cells, NF1 loss in the same compartment, and patient-derived cultures or xenografts from malignant disease. Required validation should include perivascular rounded-cell morphology, SMA/h-caldesmon expression, vascular architecture, pain-related innervation, metastatic behavior where applicable, and reversibility with NOTCH inhibition.

Current understanding and key gaps

The contemporary model is that glomus tumor is a usually benign pericytic neoplasm in which recurrent MIR143–NOTCH fusions—reported in almost 50%—provide the clearest molecular driver, with NF1 representing the best-established inherited susceptibility context. (gaudio2022notchsignallingin pages 10-11, mertens2016genefusionsin pages 19-20, carton2023erngenturistumour pages 7-8) Clinical practice remains dominated by recognition and complete excision. The main 2023–2024 translational development was molecular selection of malignant glomus tumors for NOTCH inhibition, although no subgroup efficacy estimate or approved targeted therapy has emerged. (NCT03422679 chunk 1, NCT03422679 chunk 2)

High-priority gaps are population-based epidemiology, standardized HPO frequencies and quality-of-life measures, prospective recurrence and survival cohorts, harmonized malignant-risk criteria, validated prognostic biomarkers, single-cell/spatial profiling, and disease-specific experimental models. Ontology curation should preserve the boundary between soft-tissue glomus tumor, GLMN-associated glomuvenous malformation, and head-and-neck paraganglioma.

References

1. (NCT03422679 chunk 1): Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies. Cellestia Biotech AG. 2017. ClinicalTrials.gov Identifier: NCT03422679

2. (NCT03422679 chunk 2): Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies. Cellestia Biotech AG. 2017. ClinicalTrials.gov Identifier: NCT03422679

3. (gaudio2022notchsignallingin pages 10-11): Francesca Del Gaudio, Dongli Liu, and Urban Lendahl. Notch signalling in healthy and diseased vasculature. Open Biology, Apr 2022. URL: https://doi.org/10.1098/rsob.220004, doi:10.1098/rsob.220004. This article has 68 citations and is from a peer-reviewed journal.

4. (carton2023erngenturistumour pages 7-8): Charlotte Carton, D. Gareth Evans, Ignacio Blanco, Reinhard E. Friedrich, Rosalie E. Ferner, Said Farschtschi, Hector Salvador, Amedeo A. Azizi, Victor Mautner, Claas Röhl, Sirkku Peltonen, Stavros Stivaros, Eric Legius, Rianne Oostenbrink, Joan Brunet, Frank Van Calenbergh, Catherine Cassiman, Thomas Czech, María José Gavarrete de León, Henk Giele, Susie Henley, Conxi Lazaro, Vera Lipkovskaya, Eamonn R. Maher, Vanessa Martin, Irene Mathijssen, Enrico Opocher, Ana Elisabete Pires, Thomas Pletschko, Eirene Poupaki, Vita Ridola, Andre Rietman, Thorsten Rosenbaum, Alastair Santhouse, Astrid Sehested, Ian Simmons, Walter Taal, and Anja Wagner. Ern genturis tumour surveillance guidelines for individuals with neurofibromatosis type 1. eClinicalMedicine, 56:101818, Feb 2023. URL: https://doi.org/10.1016/j.eclinm.2022.101818, doi:10.1016/j.eclinm.2022.101818. This article has 123 citations and is from a peer-reviewed journal.

5. (agaram2019gli1amplificationsexpandthe pages 1-2): Narasimhan P. Agaram, Lei Zhang, Yun-Shao Sung, Samuel Singer, Todd Stevens, Carlos N. Prieto-Granada, Justin A. Bishop, Benjamin A. Wood, David Swanson, Brendan C. Dickson, and Cristina R. Antonescu. Gli1-amplifications expand the spectrum of soft tissue neoplasms defined by gli1 gene fusions. Modern Pathology, 32:1617-1626, Nov 2019. URL: https://doi.org/10.1038/s41379-019-0293-x, doi:10.1038/s41379-019-0293-x. This article has 117 citations and is from a domain leading peer-reviewed journal.

6. (mertens2016genefusionsin pages 19-20): Fredrik Mertens, Cristina R. Antonescu, and Felix Mitelman. Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes. Genes, 55:291-310, Apr 2016. URL: https://doi.org/10.1002/gcc.22335, doi:10.1002/gcc.22335. This article has 165 citations.

7. (agaram2019gli1amplificationsexpandthe pages 2-4): Narasimhan P. Agaram, Lei Zhang, Yun-Shao Sung, Samuel Singer, Todd Stevens, Carlos N. Prieto-Granada, Justin A. Bishop, Benjamin A. Wood, David Swanson, Brendan C. Dickson, and Cristina R. Antonescu. Gli1-amplifications expand the spectrum of soft tissue neoplasms defined by gli1 gene fusions. Modern Pathology, 32:1617-1626, Nov 2019. URL: https://doi.org/10.1038/s41379-019-0293-x, doi:10.1038/s41379-019-0293-x. This article has 117 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00